002020 京新药业
已收盘 07-09 15:00:00
资讯
新帖
简况
京新药业：回购账户仅用于存放已买入库存股，无卖出
证券之星 · 07-04
京新药业：回购账户仅用于存放已买入库存股，无卖出
7月4日京新药业（002020）龙虎榜数据：游资作手新一上榜
证券之星 · 07-04
7月4日京新药业（002020）龙虎榜数据：游资作手新一上榜
京新药业涨10.02%，开源证券二个月前给出“买入”评级
证券之星 · 07-04
京新药业涨10.02%，开源证券二个月前给出“买入”评级
异动快报：京新药业（002020）7月4日13点0分触及涨停板
证券之星 · 07-04
异动快报：京新药业（002020）7月4日13点0分触及涨停板
京新药业：基于失眠领域市场规模和潜力推进地达西尼商业化
证券之星 · 07-04
京新药业：基于失眠领域市场规模和潜力推进地达西尼商业化
京新药业：JX2201是公司一款小分子降血脂的创新药
证券之星 · 07-04
京新药业：JX2201是公司一款小分子降血脂的创新药
京新药业：地达西尼生产和销售工作在正常推进中
证券之星 · 06-30
京新药业：地达西尼生产和销售工作在正常推进中
京新药业：公司大股东未参与转融通业务
证券之星 · 06-30
京新药业：公司大股东未参与转融通业务
京新药业：公司大股东暂未有增持计划
证券之星 · 06-20
京新药业：公司大股东暂未有增持计划
京新药业：公司会努力做好入院工作和学术推广活动
证券之星 · 06-19
京新药业：公司会努力做好入院工作和学术推广活动
京新药业：公司会在定期报告中披露报告期末的股东人数信息
证券之星 · 06-16
京新药业：公司会在定期报告中披露报告期末的股东人数信息
京新药业：公司的大股东未参与转融通业务
证券之星 · 06-10
京新药业：公司的大股东未参与转融通业务
每周股票复盘：京新药业（002020）已回购4,716.1295万股，成交总金额60,730.64万元
证券之星 · 06-06
每周股票复盘：京新药业（002020）已回购4,716.1295万股，成交总金额60,730.64万元
京新药业：公司回购的主要目的是股权激励或员工持股计划
证券之星 · 06-05
京新药业：公司回购的主要目的是股权激励或员工持股计划
京新药业：目前股权激励或员工持股计划方案暂未确定
证券之星 · 06-03
京新药业：目前股权激励或员工持股计划方案暂未确定
京新药业：公司回购的主要目的是股权激励或员工持股计划
证券之星 · 05-29
京新药业：公司回购的主要目的是股权激励或员工持股计划
京新药业：该项目已退出投资，项目的开发进展已经终止
证券之星 · 05-28
京新药业：该项目已退出投资，项目的开发进展已经终止
每周股票复盘：京新药业（002020）2024年度权益分派实施，调整回购股份价格上限
证券之星 · 05-24
每周股票复盘：京新药业（002020）2024年度权益分派实施，调整回购股份价格上限
京新药业：公司回购的主要目的是股权激励或员工持股计划
证券之星 · 05-23
京新药业：公司回购的主要目的是股权激励或员工持股计划
京新药业：地达西尼是公司上市的第一个创新药对公司具有里程碑意义所以公司会努力做好销售工作
证券之星 · 05-23
京新药业：地达西尼是公司上市的第一个创新药对公司具有里程碑意义所以公司会努力做好销售工作
加载更多
公司概况
公司名称：
浙江京新药业股份有限公司
所属行业：
医药制造业
上市日期：
2004-07-15
主营业务：
浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。
发行价格：
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":15.16,"timestamp":1752044622000,"preClose":15.11,"halted":0,"volume":34199198,"delay":0,"changeRate":0.0033,"floatShares":724000000,"shares":861000000,"eps":0.8177,"marketStatus":"已收盘","change":0.05,"latestTime":"07-09 15:00:00","open":15.06,"high":15.45,"low":14.87,"amount":517000000,"amplitude":0.0384,"askPrice":15.17,"askSize":588,"bidPrice":15.16,"bidSize":101,"shortable":0,"etf":0,"ttmEps":0.8177,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752111000000},"marketStatusCode":5,"adr":0,"adjPreClose":15.11,"symbolType":"stock","openAndCloseTimeList":[[1752024600000,1752031800000],[1752037200000,1752044400000]],"highLimit":16.62,"lowLimit":13.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.29,"roa":"--","peRate":18.539807,"roe":"2.77%","epsLYR":0.83,"committee":0.216258,"marketValue":13053000000,"turnoverRate":0.0472,"status":0,"floatMarketCap":10975000000},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2548962543","title":"京新药业：回购账户仅用于存放已买入库存股，无卖出","url":"https://stock-news.laohu8.com/highlight/detail?id=2548962543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548962543?lang=zh_cn&edition=full","pubTime":"2025-07-04 20:52","pubTimestamp":1751633551,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)07月04日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司回购帐户股份参与公司股卖出吗？还是只买不卖？京新药业回复：您好！回购账户仅用于存放已买入库存股，无卖出。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400035933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2548536172","title":"7月4日京新药业（002020）龙虎榜数据：游资作手新一上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2548536172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548536172?lang=zh_cn&edition=full","pubTime":"2025-07-04 17:13","pubTimestamp":1751620382,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年7月4日公布的交易公开信息显示，京新药业因日涨幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月4日收盘，京新药业报收于14.93元，上涨10.02%，涨停，换手率11.2%，成交量81.07万手，成交额11.82亿元。从龙虎榜公布的当日买卖数据来看，北向资金合计净买入4863.98万元。作手新一等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400027191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2548651133","title":"京新药业涨10.02%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2548651133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548651133?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:24","pubTimestamp":1751617459,"startTime":"0","endTime":"0","summary":"今日京新药业涨10.02%，收盘报14.93元。2025年4月7日，开源证券研究员余汝意,刘艺发布了对京新药业的研报《公司信息更新报告：存量业务稳中提质，创新药带来新增量》，该研报对京新药业给出“买入”评级。研报中预计公司2025-2027年归母净利润为8.22、9.53及11.06亿元，，EPS为0.95元、1.11元和1.28元，当前股价对应PE为15.4、13.2以及11.4倍，维持公司“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为平安证券的臧文清。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400025508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002020"],"gpt_icon":0},{"id":"2548356204","title":"异动快报：京新药业（002020）7月4日13点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2548356204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548356204?lang=zh_cn&edition=full","pubTime":"2025-07-04 13:05","pubTimestamp":1751605526,"startTime":"0","endTime":"0","summary":"证券之星7月4日盘中消息，13点0分京新药业触及涨停板。目前价格14.93，上涨10.02%。其所属行业化学制药目前上涨。领涨股为广生堂。该股为阿尔茨海默病，眼科，创新药概念热股，当日阿尔茨海默病概念上涨1.17%，眼科概念上涨0.67%，创新药概念上涨0.67%。7月4日的资金流向数据方面，主力资金净流出826.64万元，占总成交额1.37%，游资资金净流出2307.64万元，占总成交额3.82%，散户资金净流入3134.28万元，占总成交额5.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400017833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2548339196","title":"京新药业：基于失眠领域市场规模和潜力推进地达西尼商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2548339196","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548339196?lang=zh_cn&edition=full","pubTime":"2025-07-04 08:52","pubTimestamp":1751590333,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)07月04日在投资者关系平台上答复投资者关心的问题。投资者提问：据悉公司新建的0.9吨地达西尼生产线今年底明年初就竣工，可以新增销售额35亿以上，公司是基于什么原因认为未来京新药业的地达西尼销售可以达到如此规模？京新药业回复：您好！目前地达西尼产品的生产线已经在正常生产中，基于失眠领域的市场规模和潜力，公司会努力推进地达西尼的商业化工作，争取更好的销售成果。后续若有新建生产线需求，敬请关注公司公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400006333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2548433916","title":"京新药业：JX2201是公司一款小分子降血脂的创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2548433916","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548433916?lang=zh_cn&edition=full","pubTime":"2025-07-04 08:49","pubTimestamp":1751590149,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)07月04日在投资者关系平台上答复投资者关心的问题。投资者提问：市场传闻京新药业JX2201正在谈BD交易，请问预计今年可以完成交易吗？这款药如果完成BD，是不是可以在欧美市场以及其它市场销售？京新药业回复：您好！JX2201是公司一款小分子降血脂的创新药，目前处在临床I期。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400006285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","06978","BK0239","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2547057275","title":"京新药业：地达西尼生产和销售工作在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2547057275","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547057275?lang=zh_cn&edition=full","pubTime":"2025-06-30 15:37","pubTimestamp":1751269026,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问吕董，公司地达西尼年产0.9吨的新建产线年底就要完成，加上现有产能，那公司预计地达西尼的未来年销售额是不是可以达到40亿以上的单品销售，不然为什么要在现有产能基础上新建年产0.9吨地达西尼的生产线？目前地达西尼的生产和销售工作在正常推进中，希望尽快实现销售放量，为公司贡献收入和利润。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000015233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2547057796","title":"京新药业：公司大股东未参与转融通业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2547057796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547057796?lang=zh_cn&edition=full","pubTime":"2025-06-30 15:34","pubTimestamp":1751268874,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司股东吕岳英家族和上海国际集团是否参与了转融通和量化业务？京新药业回复：您好！公司大股东未参与转融通业务。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000015047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2544405127","title":"京新药业：公司大股东暂未有增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2544405127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544405127?lang=zh_cn&edition=full","pubTime":"2025-06-20 20:54","pubTimestamp":1750424055,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月19日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司高层决定拿全体股东的巨资回购公司二级市场股份，高层如此看好公司前景为什么不自己增持公司股份？京新药业回复：您好！公司大股东暂未有增持计划。公司多年来坚持分红回报股东，也会努力维护全体股东的利益。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000036320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2544156396","title":"京新药业：公司会努力做好入院工作和学术推广活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2544156396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544156396?lang=zh_cn&edition=full","pubTime":"2025-06-19 16:18","pubTimestamp":1750321109,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月19日在投资者关系平台上答复投资者关心的问题。投资者提问：地达西尼宣传几年了，也上市了，怎么还没有推广到湖南省常德市来？？？京新药业回复：您好！公司会努力做好入院工作和学术推广活动，尽可能的广覆盖各省市的医院，为患者带来便利。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061900022204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2543251956","title":"京新药业：公司会在定期报告中披露报告期末的股东人数信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2543251956","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543251956?lang=zh_cn&edition=full","pubTime":"2025-06-16 15:39","pubTimestamp":1750059566,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业06月16日在投资者关系平台上答复投资者关心的问题。请问把带有时间和姓名的股票交易软件持仓截图和身份证一并扫描发送至公司邮箱，可以获知 非定期报告相关时点的股东人数吗？顺祝健康，快乐 【比如截至到2025年6月10日贵公司的股东人数是多少？.,京新药业回复：您好！公司会在定期报告中披露报告期末的股东人数信息。对于非定期报告的股东人数，股东可向公司董秘办提供股东证明，公司经核实后予以提供。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600013985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2542998473","title":"京新药业：公司的大股东未参与转融通业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2542998473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542998473?lang=zh_cn&edition=full","pubTime":"2025-06-10 16:39","pubTimestamp":1749544757,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司前几大股东，哪几家参与转融通业务？京新药业回复：您好！公司的大股东未参与转融通业务。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061000024866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2541896188","title":"每周股票复盘：京新药业（002020）已回购4,716.1295万股，成交总金额60,730.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541896188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541896188?lang=zh_cn&edition=full","pubTime":"2025-06-07 06:09","pubTimestamp":1749247758,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘，京新药业报收于13.32元，较上周的13.1元上涨1.68%。本周，京新药业6月4日盘中最高价报13.89元。预计回购股份数量约1,351万股至2,703万股，约占总股本的1.57%-3.14%。回购期限为12个月。2024年年度权益分派实施后，回购价格上限调整为14.47元/股，预计回购股份数量约2,419万股至4,838万股，占总股本的2.81%-5.62%。截至2025年5月31日，公司已回购4,716.1295万股，占总股本5.48%，最高成交价14.41元/股，最低成交价11.86元/股，成交总金额60,730.64万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700007804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2541078739","title":"京新药业：公司回购的主要目的是股权激励或员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2541078739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541078739?lang=zh_cn&edition=full","pubTime":"2025-06-05 20:51","pubTimestamp":1749127919,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司已回购的5千万股，这些股份参与转融通业务或请正面回答。对倒卖买？京新药业回复：您好！公司回购的主要目的是股权激励或员工持股计划，到期无法使用完部分会按规定注销。回购股份不参与转融通业务。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060500033506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2540142714","title":"京新药业：目前股权激励或员工持股计划方案暂未确定","url":"https://stock-news.laohu8.com/highlight/detail?id=2540142714","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540142714?lang=zh_cn&edition=full","pubTime":"2025-06-03 08:48","pubTimestamp":1748911692,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司回购部分用于股权激励，然而目前已回购6亿多元了，基本完成，但乃未出台股权激励计划什么原因？就这样的效率还是其它不为人知的原因？京新药业回复：您好！目前股权激励或员工持股计划方案暂未确定，敬请关注公司后续相关公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060300004571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2539638002","title":"京新药业：公司回购的主要目的是股权激励或员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2539638002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539638002?lang=zh_cn&edition=full","pubTime":"2025-05-29 20:55","pubTimestamp":1748523328,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，公司回购的近5千万股，是否是全部入库冻结还是转融通或参与二级市场对倒？京新药业回复：您好！公司回购的主要目的是股权激励或员工持股计划，到期无法使用完部分会按规定注销。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052900035414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2538634440","title":"京新药业：该项目已退出投资，项目的开发进展已经终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2538634440","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538634440?lang=zh_cn&edition=full","pubTime":"2025-05-28 16:12","pubTimestamp":1748419960,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月28日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，从以色列引进的神经取检药械现已到什么程度了？大约什么时间上市？京新药业回复：您好！该项目已退出投资，项目的开发进展已经终止。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052800023494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2537191657","title":"每周股票复盘：京新药业（002020）2024年度权益分派实施，调整回购股份价格上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2537191657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537191657?lang=zh_cn&edition=full","pubTime":"2025-05-24 23:20","pubTimestamp":1748100030,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘，京新药业报收于13.44元，较上周的13.38元上涨0.45%。本周，京新药业5月23日盘中最高价报13.65元。本次权益分派股权登记日为2025年5月28日，除权除息日为2025年5月29日。本次分派对象为截止2025年5月28日下午深圳证券交易所收市后，在中国结算深圳分公司登记在册的本公司全体股东。浙江京新药业股份有限公司还发布了关于调整回购股份价格上限的公告。公司将继续实施回购方案并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400015321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2537013112","title":"京新药业：公司回购的主要目的是股权激励或员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2537013112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537013112?lang=zh_cn&edition=full","pubTime":"2025-05-23 20:56","pubTimestamp":1748005018,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司吕董，每次都是答非所问什么原因？我问投入巨资7亿带来什么利益？没问公司其它事。既然投入巨资那一定得有益处非否这里面就有问题了？京新药业回复：您好！公司回购的主要目的是股权激励或员工持股计划，到期无法使用完部分会按规定注销。希望提升公司经营效率，实现公司经营目标，同时提高股东回报。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300039222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2537900974","title":"京新药业：地达西尼是公司上市的第一个创新药对公司具有里程碑意义所以公司会努力做好销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2537900974","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537900974?lang=zh_cn&edition=full","pubTime":"2025-05-23 15:45","pubTimestamp":1747986310,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)05月23日在投资者关系平台上答复投资者关心的问题。投资者提问：关于地达西尼胶囊的销售情况问题，好多个人股东问了好多次，但是公司一直讳莫如深不予正面回答。其他有创新药公司不是这样的。请问公司这样做是出于保护商业秘密，还是销售数字太差不好意思公开呢？京新药业回复：您好！地达西尼是公司上市的第一个创新药，对于公司具有里程碑意义，所以公司会努力做好销售工作，尽可能的实现销售目标。具体的销售数据敬请关注公司相关定期报告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052300019690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","06978","159992","002020","BK1161"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752097614391,"stockEarnings":[{"period":"1week","weight":0.1689},{"period":"1month","weight":0.093},{"period":"3month","weight":0.163},{"period":"6month","weight":0.2979},{"period":"1year","weight":0.4937},{"period":"ytd","weight":0.2148}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0274},{"period":"3month","weight":0.0836},{"period":"6month","weight":0.1024},{"period":"1year","weight":0.1803},{"period":"ytd","weight":0.0422}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25705人(较上一季度减少85.40%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":" 浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、传统中药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}